BioMarin Announces First Recipients of RARE Scholars Scholarship Program
BioMarin Announces First Recipients of RARE Scholars Scholarship Program Five Students with Rare Genetic Diseases Receive a Total of $20,000 for Higher Education |
[28-June-2018] |
SAN RAFAEL, Calif., June 28, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has awarded the first five recipients of the RARE Scholars program, an annual scholarship for students living with rare disease. The RARE Scholars program provides up to $20,000 to students living with mucopolysaccharidoses, phenylketonuria or Batten disease.
"We are thrilled to offer this scholarship program for the first time to students with rare genetic diseases, who have not only excelled academically, but also have overcome enormous challenges," said Jean-Jacques Bienaimé, chairman and chief executive officer of BioMarin. "We are inspired to offer scholarships to students who have excelled in spite of a disease diagnosed in childhood. It is an honor to be a part of their journeys into adulthood." The recipients of the 2018 RARE Scholars program are:
"It's amazing to see members of our community receiving these scholarships and attending college, especially because for a condition like PKU, their disease can impair their ability to learn," said Christine Brown, MS, executive director of the National PKU Alliance. "Higher education is so important, and we are thankful to BioMarin for offering this scholarship to further help people living with a rare disease." BioMarin announced its RARE Scholars program on Rare Disease Day, February 28, 2018 and began accepting applications the next day. About BioMarin About RARE Scholars
View original content with multimedia:http://www.prnewswire.com/news-releases/biomarin-announces-first-recipients-of-rare-scholars-scholarship-program-300673801.html SOURCE BioMarin Pharmaceutical Inc. | ||||||||||||
Company Codes: NASDAQ-NMS:BMRN |
© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}